Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary A Zarkin

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Pharmacoeconomics|May 18, 2005
On pharmacogenomics and cost-effectiveness analysis at the individual levelMohan V Bala, Gary A Zarkin
The American Journal of Managed Care|March 28, 2002
Application of cost-effectiveness analysis to multiple products: a practical guideMohan V Bala, Gary A Zarkin
Alcohol Research & Health : the Journal of the National Institute on Alcohol Abuse and Alcoholism|June 14, 2006
Economic evaluation of alcoholism treatmentJeremy W Bray, Gary A Zarkin
Pharmacoeconomics|June 26, 2004
Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?Mohan V Bala, Gary A Zarkin
The Journal of Mental Health Policy and Economics|April 23, 2002
Mental health, absenteeism and earnings at a large manufacturing worksiteMichael T. French, Gary A. Zarkin
Journal of Addiction Medicine|November 22, 2018
Receipt of Substance Use Disorder Treatment Among Patients Visiting PsychiatristsTami L Mark, Angélica Meinhofer, Gary A Zarkin
Evaluation Review|February 24, 2006
The costs of pursuing accreditation for methadone treatment sites: results from a national studyGary A Zarkin, Laura J Dunlap, Ghada Homsi
Health Economics|August 19, 2007
Presenting results of probabilistic sensitivity analysis: the incremental benefit curveMohan V Bala, Gary A Zarkin, Josephine Mauskopf
JAMA|July 10, 2019
Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D PlansTami L Mark, William Parish, Gary A Zarkin
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2002
Conditions for the near equivalence of cost-effectiveness and cost-benefit analysesMohan V Bala, Gary A Zarkin, Josephine A Mauskopf
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Pharmacoeconomics|May 18, 2005
On pharmacogenomics and cost-effectiveness analysis at the individual levelMohan V Bala, Gary A Zarkin
The American Journal of Managed Care|March 28, 2002
Application of cost-effectiveness analysis to multiple products: a practical guideMohan V Bala, Gary A Zarkin
Alcohol Research & Health : the Journal of the National Institute on Alcohol Abuse and Alcoholism|June 14, 2006
Economic evaluation of alcoholism treatmentJeremy W Bray, Gary A Zarkin
Pharmacoeconomics|June 26, 2004
Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?Mohan V Bala, Gary A Zarkin
The Journal of Mental Health Policy and Economics|April 23, 2002
Mental health, absenteeism and earnings at a large manufacturing worksiteMichael T. French, Gary A. Zarkin
Journal of Addiction Medicine|November 22, 2018
Receipt of Substance Use Disorder Treatment Among Patients Visiting PsychiatristsTami L Mark, Angélica Meinhofer, Gary A Zarkin
Evaluation Review|February 24, 2006
The costs of pursuing accreditation for methadone treatment sites: results from a national studyGary A Zarkin, Laura J Dunlap, Ghada Homsi
Health Economics|August 19, 2007
Presenting results of probabilistic sensitivity analysis: the incremental benefit curveMohan V Bala, Gary A Zarkin, Josephine Mauskopf
JAMA|July 10, 2019
Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D PlansTami L Mark, William Parish, Gary A Zarkin
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2002
Conditions for the near equivalence of cost-effectiveness and cost-benefit analysesMohan V Bala, Gary A Zarkin, Josephine A Mauskopf
Pageof 9